Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Gentamicin‐impregnated collagen sponge vs no dressing Pain at first postoperative dressing change (measured using a validated scale such as a visual analogue scale) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal… (2022) · Cochrane | no estimate extracted | NR | No studies |
Gentamicin‐impregnated collagen sponge vs no dressing Adverse effects (surgical site infection or allergic reaction) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dialkylcarbamoyl chloride (DACC)‐coated dressing vs alginate dressing Proportion of wounds healed at 6 months · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dialkylcarbamoyl chloride (DACC)‐coated dressing vs alginate dressing Proportion of wounds healed at 12 months · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dialkylcarbamoyl chloride (DACC)‐coated dressing vs alginate dressing Cost‐effectiveness (assessed using quality‐adjusted life years) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dialkylcarbamoyl chloride (DACC)‐coated dressing vs alginate dressing Pain at first postoperative dressing change (measured using a validated scale such as a visual analogue scale) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal… (2022) · Cochrane | no estimate extracted | NR | No studies |
Dialkylcarbamoyl chloride (DACC)‐coated dressing vs alginate dressing Adverse effects (surgical site infection or allergic reaction) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal… (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical negative pressure wound therapy vs conventional open wound healing Cost‐effectiveness (assessed using quality‐adjusted life years) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal… (2022) · Cochrane | no estimate extracted | NR | No studies |
Topical negative pressure wound therapy vs conventional open wound healing Pain at first postoperative dressing change (measured using a validated scale such as a visual analogue scale) · adults with open wounds after surgery for sacrococcygeal pilonidal sinus disease Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal… (2022) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo PTSD severity at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Propranolol vs placebo Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs placebo Dropout due to adverse events at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs placebo Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs placebo Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo Dropout due to adverse events at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo PTSD rate at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Propranolol vs placebo Dropout due to adverse events at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Propranolol vs placebo Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Duct‐to‐mucosa pancreaticojejunostomy using the modified Blumgart technique vs duct‐to‐mucosa pancreaticojejunostomy using the traditional interrupted technique Adverse events · adults undergoing open pancreaticoduodenectomy Duct‐to‐mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic… (2022) · Cochrane | no estimate extracted | NR | No studies |
Duct‐to‐mucosa pancreaticojejunostomy using the modified Blumgart technique vs duct‐to‐mucosa pancreaticojejunostomy using the traditional interrupted technique Quality of life · adults undergoing open pancreaticoduodenectomy Duct‐to‐mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic… (2022) · Cochrane | no estimate extracted | NR | No studies |
Duct‐to‐mucosa vs invagination pancreaticojejunostomy Adverse events · adults undergoing open pancreaticoduodenectomy Duct‐to‐mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic… (2022) · Cochrane | no estimate extracted | NR | No studies |
Duct‐to‐mucosa vs invagination pancreaticojejunostomy Quality of life · adults undergoing open pancreaticoduodenectomy Duct‐to‐mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic… (2022) · Cochrane | no estimate extracted | NR | No studies |
Fortification of salt with iron and iodine vs fortification of salt with iodine Blood pressure (systolic and diastolic) (mmHg) · participants were of any age or sex and from any country, regardless of baseline iron and iodine status Fortification of salt with iron and iodine versus fortification of salt with iodine alone for improving iron… (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab weekly vs placebo + 52‐week taper Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab weekly vs placebo + 52‐week taper Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab weekly vs placebo + 52‐week taper Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab weekly vs placebo + 26‐week taper Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab weekly vs placebo + 26‐week taper Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab weekly vs placebo + 26‐week taper Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab every other week vs placebo + 52‐week taper Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab every other week vs placebo + 52‐week taper Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab every other week vs placebo + 52‐week taper Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab every other week vs placebo + 26‐week taper Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab every other week vs placebo + 26‐week taper Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab every other week vs placebo + 26‐week taper Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab every 4 weeks vs placebo Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab every 4 weeks vs placebo Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey physical component score (SF‐36 PCS) · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab every 4 weeks vs placebo Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Tocilizumab every 4 weeks vs placebo Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis Tocilizumab for giant cell arteritis (2022) · Cochrane | no estimate extracted | NR | No studies |
Pulmonary rehabilitation vs usual care Adverse events · Adults with asthma Pulmonary rehabilitation versus usual care for adults with asthma (2022) · Cochrane | no estimate extracted | NR | No studies |
Nebulised magnesium sulfate + standard care vs placebo + standard care Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Magnesium sulfate vs standard care (ipratropium bromide) Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Magnesium sulfate vs standard care (ipratropium bromide) Change in oxygen saturation (SaO2) · acute exacerbations of chronic obstructive pulmonary disease Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Magnesium sulfate vs standard care (ipratropium bromide) Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Magnesium sulfate vs standard care (ipratropium bromide) Lung function: FEV1 at 60 min · acute exacerbations of chronic obstructive pulmonary disease Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Gingko biloba with concurrent intervention vs concurrent intervention only Other adverse effects (gastrointestinal upset, headache, allergic reaction) · adults with tinnitus Ginkgo biloba for tinnitus (2022) · Cochrane | no estimate extracted | NR | No studies |
Gingko biloba with concurrent intervention vs concurrent intervention only Serious adverse effects (bleeding or seizures) · adults with tinnitus Ginkgo biloba for tinnitus (2022) · Cochrane | no estimate extracted | NR | No studies |
Gingko biloba with concurrent intervention vs concurrent intervention only Health‐related quality of life · adults with tinnitus Ginkgo biloba for tinnitus (2022) · Cochrane | no estimate extracted | NR | No studies |